ENXTPA:ABVXBiotechs
Assessing Abivax (ENXTPA:ABVX) Valuation After Phase 3 Progress Cash Runway Extension And New Commercial Leadership
ABIVAX Société Anonyme (ENXTPA:ABVX) is back in focus after its recent update on the Phase 3 ABTECT-UC trial for ulcerative colitis, its extended cash runway into Q4 2027, and the appointment of new commercial leadership.
See our latest analysis for ABIVAX Société Anonyme.
The recent Phase 3 update and extended cash runway appear to sit against fading short term momentum, with a 30 day share price return of 4.88% decline and year to date share price return of 16.13% decline. At the same time,...